The future of the oral pharmacotherapy of male erectile dysfunction: things to come
- 1 May 2007
- journal article
- review article
- Published by Taylor & Francis in Emerging Drugs
- Vol. 12 (2), 219-228
- https://doi.org/10.1517/14728214.12.2.219
Abstract
The convincing clinical data on the use of the orally active phosphodiesterase inhibitors sildenafil, vardenafil and tadalafil for the treatment of male erectile dysfunction have boosted research activities on the physiology of the male erectile mechanism. This included both peripheral intracellular signal transduction in the corpus cavernosum as well as central brain and spinal cord pathways controlling penile erection. This work provided the basis for the development and introduction of several new therapeutic modalities into the management of erectile dysfunction, some of which are already offered to the patients. As the concept of ‘taking a pill’ as a cure for an illness or the relief of symptoms of a disease has become widely accepted by the consumers, the pharmacologic treatment of erectile dysfunction has primarily focussed on selective, orally available drugs acting by influencing intracellular or central regulatory mechanisms, combining a high response rate and the advantage of an on-demand intake. These agents are regarded as more efficacious, and have a faster onset of drug action in the target tissue and an improved effect to side-effect ratio. The purpose of this review is to describe the major novel and evolving pharmacologic advances in the field of oral pharmacotherapy for the treatment of male erectile dysfunction.Keywords
This publication has 74 references indexed in Scilit:
- Chronic Administration of an Oral Rho Kinase Inhibitor Prevents the Development of Vasculogenic Erectile Dysfunction in a Rat ModelThe Journal of Sexual Medicine, 2006
- The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunctionInternational Journal Of Impotence Research, 2005
- Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive ratsInternational Journal Of Impotence Research, 2004
- Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase βInternational Journal Of Impotence Research, 2003
- Growth hormone, somatomedins and men's healthThe Aging Male, 2002
- RhoA/Rho-kinase: a novel player in the regulation of penile erectionInternational Journal Of Impotence Research, 2001
- Guanylate cyclase and the ⋅NO/cGMP signaling pathwayBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1999
- Effects of Growth Hormone Replacement Therapy on IGF-Related Parameters and on the Pituitary-Gonadal Axis in GH-Deficient MalesHormone Research in Paediatrics, 1998
- Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study.JCI Insight, 1996
- Effects of the nitric oxide synthase inhibitor NG‐nitro‐L‐arginine on the erectile response to cavernous nerve stimulation in the rabbitActa Physiologica Scandinavica, 1991